Regeneron Pharmaceuticals announced a strategic collaboration with TriNetX that includes a $200 million investment and grants the company exclusive access to TriNetX’s federated network of 300 million de‑identified patient records worldwide, including roughly 170 million in the United States. The deal gives Regeneron the ability to link its Regeneron Genetics Center (RGC) sequencing and proteomics data to real‑world clinical information, creating a richer, more comprehensive health database.
The RGC has already sequenced more than 2 million individuals and maintains a database of nearly 3 million sequenced exomes paired with de‑identified health records. By integrating TriNetX’s data, Regeneron will expand its world‑leading genomic and proteomic repository, a key driver of its pipeline of 45 clinical candidates across ophthalmology, immunology and other therapeutic areas.
The partnership is designed to accelerate drug discovery, enhance AI training algorithms, and support the development of future digital health solutions. By combining large‑scale phenotypic data with genomic and proteomic insights, Regeneron aims to identify new therapeutic targets more efficiently and streamline clinical development, thereby strengthening its competitive position in markets where data‑driven innovation is increasingly critical.
"This is a major milestone for the RGC and a powerful new pathway to achieve our core mission: building the world's largest and richest human health database to drive drug development and pioneer digital health solutions for consumers, patients and providers," said Aris Baras, Senior Vice President and Head of the Regeneron Genetics Center. "We are looking forward to working with the TriNetX team. Our RGC strategic investments catalyze innovation, driving advancements in cutting‑edge technologies that accelerate drug discovery and development, as well as help us develop innovative digital health solutions. This deal represents the latest and one of our most significant collaborations, and we look forward to continuing to expand our network of top‑tier partners as we pursue our mission," added Andrew Deubler, Senior Vice President, RGC Chief Business and Administrative Officer. "We are delighted to work with Regeneron, and specifically the Regeneron Genetics Center team, to advance human health through the application of intelligence‑driven information technology," said Jeff Margolis, TriNetX Executive Chairman.
The collaboration positions Regeneron to leverage advanced data analytics and AI to uncover new therapeutic targets and accelerate clinical development, reinforcing its leadership in ophthalmology and immunology. The expanded dataset will also support the company's broader strategy of building the world's largest and richest human health database, a cornerstone of its long‑term growth and innovation agenda.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.